Business
Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET
Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer ...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n \n \n \n Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Partial responses achieved in all patients in cohort's\n \n 1b\n \n portion\n \n \n \n \n Expansion criteria for pancreatic cancer cohort has been met to allow for additional patient enrollment\n \n \n \n \n Data suggest pelareorep synergistically combines with chemotherapy and checkpoint inhibition in a highly challenging indication and are featured in an abstract at the ESMO World Congress on Gastrointestinal Cancer\n \n \n \n \n \n SAN DIEGO\n \n and\n \n CALGARY, AB\n \n \n ,\n \n \n June 28, 2022\n \n \n /CNW/ -- Oncolytics Biotech\n \n ®\n \n Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the pancreatic cancer cohort of the multi-indication phase 1/2 GOBLET study has met the efficacy expansion criteria for Stage 1 of the trial. The data from the phase\n \n 1b\n \n portion of this cohort, which are featured in an abstract accepted for a poster presentation at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022, show a strong efficacy signal as evidenced by all patients achieving a partial response (n = 3). An independent safety review noted no toxicity concerns in these patients. The trial's metastatic colorectal and advanced anal cancer cohorts are proceeding as planned.\n \n \n \n \n \n \n \n \n \n The GOBLET study's pancreatic cancer cohort is evaluating the safety and efficacy of pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab and the chemotherapeutic agents gemcitabine and nab-paclitaxel. Per the study's Simon two-stage design, any cohort meeting a pre-specified efficacy threshold in Stage 1 (defined as achieving a minimum number of objective radiologic responses by week 16) may be expanded to enroll additional patients in an optional Stage 2 study expansion. In addition to evaluating the safety and efficacy of pelareorep-atezolizuma...